Nutra Pharma Corp.
NPHC
$0.00
$0.000.00%
OTC PK
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -37.60% | 28.02% | 82.41% | 598.20% | 732.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -37.60% | 28.02% | 82.41% | 598.20% | 732.69% |
| Cost of Revenue | -43.29% | -39.66% | 32.07% | 260.42% | 12.31% |
| Gross Profit | -34.70% | 68.62% | 185.81% | 1,221.79% | 467.95% |
| SG&A Expenses | -79.91% | -7.88% | -28.00% | 58.70% | 154.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -77.75% | -11.60% | -19.54% | 67.48% | 137.05% |
| Operating Income | 86.27% | 29.89% | 46.56% | -29.28% | -105.84% |
| Income Before Tax | -107.52% | -148.25% | 56.77% | -111.82% | 49.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -107.52% | -148.25% | 56.77% | -111.82% | 49.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -107.52% | -148.25% | 56.77% | -111.82% | 49.01% |
| EBIT | 86.27% | 29.89% | 46.56% | -29.28% | -105.84% |
| EBITDA | 86.38% | 30.49% | 47.23% | -29.73% | -105.92% |
| EPS Basic | -100.00% | -100.00% | 100.00% | -114.29% | 33.33% |
| Normalized Basic EPS | -100.00% | -- | -- | -100.00% | 50.00% |
| EPS Diluted | -100.00% | -- | 100.00% | -133.33% | -66.67% |
| Normalized Diluted EPS | -100.00% | -- | -- | -100.00% | -50.00% |
| Average Basic Shares Outstanding | 0.32% | 0.28% | 1.72% | 3.37% | 3.70% |
| Average Diluted Shares Outstanding | -75.47% | -51.19% | 1.72% | -47.59% | 324.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |